<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26678993</article-id><article-id pub-id-type="pmc">4683045</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0143953</article-id><article-id pub-id-type="publisher-id">PONE-D-15-13132</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Xenotransplantation of Human Cardiomyocyte Progenitor Cells Does Not Improve Cardiac Function in a Porcine Model of Chronic Ischemic Heart Failure. Results from a Randomized, Blinded, Placebo Controlled Trial</article-title><alt-title alt-title-type="running-head">Cardiomyocyte Progenitor Cells in a Pig Model of Myocardial Ischemia</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jansen of Lorkeers</surname><given-names>Sanne J.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gho</surname><given-names>Johannes M. I. H.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Koudstaal</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>van Hout</surname><given-names>Gerardus P. J.</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zwetsloot</surname><given-names>Peter Paul M.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>van Oorschot</surname><given-names>Joep W. M.</given-names></name><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>van Eeuwijk</surname><given-names>Esther C. M.</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Leiner</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hoefer</surname><given-names>Imo E.</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Goumans</surname><given-names>Marie-Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Doevendans</surname><given-names>Pieter A.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sluijter</surname><given-names>Joost P. G.</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chamuleau</surname><given-names>Steven A. J.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>ICIN - Netherlands Heart Institute, Utrecht, the Netherlands</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Experimental Cardiology Laboratory, University Medical Center Utrecht, the Netherlands</addr-line>
</aff><aff id="aff004">
<label>4</label>
<addr-line>Department of Radiology, University Medical Center Utrecht, Utrecht, the Netherlands</addr-line>
</aff><aff id="aff005">
<label>5</label>
<addr-line>Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Tang</surname><given-names>Yaoliang</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Georgia Regents University, UNITED STATES</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: SJ PD JS SC. Performed the experiments: SJ JG SK GH PZ JO. Analyzed the data: SJ JG GH PZ. Contributed reagents/materials/analysis tools: JO EE MG TL IH. Wrote the paper: SJ JG PD SC.</p></fn><corresp id="cor001">* E-mail: <email>s.a.j.chamuleau@umcutrecht.nl</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>12</issue><elocation-id>e0143953</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>11</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Jansen of Lorkeers et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Jansen of Lorkeers et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0143953.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Recently cardiomyocyte progenitor cells (CMPCs) were successfully isolated from fetal and adult human hearts. Direct intramyocardial injection of human CMPCs (hCMPCs) in experimental mouse models of acute myocardial infarction significantly improved cardiac function compared to controls.</p></sec><sec id="sec002"><title>Aim</title><p>Here, our aim was to investigate whether xenotransplantation via intracoronary infusion of fetal hCMPCs in a pig model of chronic myocardial infarction is safe and efficacious, in view of translation purposes.</p></sec><sec id="sec003"><title>Methods &#x00026; Results</title><p>We performed a randomized, blinded, placebo controlled trial. Four weeks after ischemia/reperfusion injury by 90 minutes of percutaneous left anterior descending artery occlusion, pigs (n = 16, 68.5 &#x000b1; 5.4 kg) received intracoronary infusion of 10 million fetal hCMPCs or placebo. All animals were immunosuppressed by cyclosporin (CsA). Four weeks after infusion, endpoint analysis by MRI displayed no difference in left ventricular ejection fraction, left ventricular end diastolic and left ventricular end systolic volumes between both groups. Serial pressure volume (PV-)loop and echocardiography showed no differences in functional parameters between groups at any timepoint. Infarct size at follow-up, measured by late gadolinium enhancement MRI showed no difference between groups. Intracoronary pressure and flow measurements showed no signs of coronary obstruction 30 minutes after cell infusion. No premature death occurred in cell treated animals.</p></sec><sec id="sec004"><title>Conclusion</title><p>Xenotransplantation via intracoronary infusion of hCMPCs is feasible and safe, but not associated with improved left ventricular performance and infarct size compared to placebo in a porcine model of chronic myocardial infarction.</p></sec></abstract><funding-group><funding-statement>This research forms part of the Project P1.04 SMARTCARE of the research program of the BioMedical Materials Institute, co-funded by the Dutch Ministry of Economic Affairs, Agriculture and Innovation. The financial contribution of the Nederlandse Hartstichting is gratefully acknowledged. This project is co-funded by a grant from the Alexandre Suerman program for MD/PhD students of the University Medical Center Utrecht, the Netherlands. This work is also funded by the Netherlands CardioVascular Research Initiative (CVON): the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Sciences. Professor Leiner is recipient of a NOW Clinical Fellowship (90700432).</funding-statement></funding-group><counts><fig-count count="8"/><table-count count="3"/><page-count count="19"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>The heart has regenerative capacity as it harbours a pool of cardiac stem cells.[<xref rid="pone.0143953.ref001" ref-type="bibr">1</xref>] However, this is clearly not sufficient to repair the damage caused by myocardial infarction (MI) to prevent the development of heart failure. The number of stem cells available might just be too little. <italic>Ex vivo</italic> expansion and reapplication of cardiac stem cells to the injured heart was proposed, however isolation of these cardiac stem cells remains challenging. Our lab succeeded in isolating fetal and adult cardiomyocyte progenitor cells (CMPC) from mouse and human hearts based on the stem cell antigen Sca-1.[<xref rid="pone.0143953.ref002" ref-type="bibr">2</xref>] CMPCs can successfully been differentiated in cardiomyocytes, endothelial cells and smooth muscle cells <italic>in vitro</italic>. [<xref rid="pone.0143953.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="pone.0143953.ref004" ref-type="bibr">4</xref>] These hCMPC-derived cardiomyocytes have functional gap junctions, enabling metabolic and electrical coupling of cells.[<xref rid="pone.0143953.ref004" ref-type="bibr">4</xref>] Intra-myocardial injection of hCMPCs in a mouse model of acute MI led to engraftment of 3,5% of cells, differentiation towards coupled cardiomyocytes, increased vascular density, and to improved cardiac function. [<xref rid="pone.0143953.ref005" ref-type="bibr">5</xref>] These promising results led to the current large animal study, as a next step towards potential clinical application of hCMPCs. Since the greatest burden of ischemic heart disease is based on chronic ischemic heart failure, hCMPCs were tested in a chronic disease model.</p><p>In the current study, fetal hCMPCs were intracoronary administered in a porcine model of chronic ischemia/reperfusion injury (I/R). We hypothesized that this strategy is safe, improves left ventricular performance and reduces infarct size compared to placebo.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods</title><sec id="sec007" sec-type="materials|methods"><title>Experimental design</title><p>All animal experiments were executed in conformance with the &#x02018;Guide for the Care and Use of Laboratory Animals&#x02019;. The experiment was evaluated and approved by the Animal Experiments Committee of the Utrecht University, the Netherlands (permit number 2012.II.09.145).</p><p>Animals were subjected to I/R, randomized to fetal hCMPC or placebo infusion 4 weeks later and endpoint analyses were performed 4 weeks after stem cell injection (see study protocol, <xref rid="pone.0143953.g001" ref-type="fig">Fig 1</xref>). All animals were immunosuppressed by Cyclosporin A (CsA) to facilitate xenogeneic cell treatment. Based on a power calculation (estimated effect 7.5% [<xref rid="pone.0143953.ref006" ref-type="bibr">6</xref>], standard deviation of 5%, a power of 0.9 and alpha of 0.05) 8 pigs per group were needed. Animals that died before endpoint analysis were supplemented.</p><fig id="pone.0143953.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0143953.g001</object-id><label>Fig 1</label><caption><title>Study protocol.</title></caption><graphic xlink:href="pone.0143953.g001"/></fig><p>Animals were randomized after surviving the initial I/R, using a computer based random order generator. Cell and placebo infusion as well as data analysis were performed in a blinded fashion (investigators, technicians and animal caretakers). Deblinding was performed after collecting and analysing all data.</p><p>The primary endpoint of this study was defined as left ventricular ejection fraction (EF) at the end of follow-up, measured by magnetic resonance imaging (MRI). Secondary endpoints were left ventricular end diastolic volume and left ventricular end systolic volume (EDV and ESV) measured by MRI, infarct size measured by <italic>ex vivo</italic> gross macroscopy after incubation with triphenyltetrazolium chloride (TTC) and late gadolinium enhancement (LGE) MRI, functional parameters serially measured by pressure volume (PV-)loop and echocardiography, coronary microvascular function by intracoronary pressure- and flow measurements and vascular density and fibrosis on histology.</p></sec><sec id="sec008"><title>Cell isolation</title><p>Cells were isolated from fetal human heart tissue (derived after elective abortion with informed consent) and cultured as described before. [<xref rid="pone.0143953.ref002" ref-type="bibr">2</xref>] Shortly, tissue was minced, incubated with collagenase and grinded through a cell strainer. Cells were incubated with anti-Sca-1 microbeads and separated using a MiniMACS magnet (Miltenyi Biotec, Leiden, the Netherlands). hCMPCs were collected and dissolved in growth medium containing endothelial growth medium (EGM-2, Cambrex, CC-4176), FBS, penicillin/streptomycin, non-essential amino acids and bFGF. After attachment of the cells, cells were split after +/- 3 days at 80&#x02013;90% confluence in a 1:6 fashion. All pigs received hCMPCs of passage 5&#x02013;7 from the same donor.</p></sec><sec id="sec009"><title>Cell characteristics</title><p>Fetal hCMPCs are characterized by expression of CD105, CD31, Sca-1 and c-kit and absence of expression of CD45, CD14,CD34 and CD133.[<xref rid="pone.0143953.ref002" ref-type="bibr">2</xref>] Further cell characteristics are provided in <xref rid="pone.0143953.t001" ref-type="table">Table 1</xref>. CMPCs from fetal and adult human hearts showed differentiation into spontaneously beating and electrically coupled cardiomyocytes after stimulation with 5-azacytidine and TGF&#x003b2;.[<xref rid="pone.0143953.ref004" ref-type="bibr">4</xref>] Differentiation into endothelial cells and smooth muscle cells can be achieved by exposure to vascular endothelial growth factor (VEGF).[<xref rid="pone.0143953.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="pone.0143953.ref004" ref-type="bibr">4</xref>] CMPCs in culture are presented in <xref rid="pone.0143953.s001" ref-type="supplementary-material">S1 Fig</xref>.</p><table-wrap id="pone.0143953.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0143953.t001</object-id><label>Table 1</label><caption><title>CMPC characteristics.</title></caption><alternatives><graphic id="pone.0143953.t001g" xlink:href="pone.0143953.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">Passage</td><td align="left" rowspan="1" colspan="1">5&#x02013;7</td></tr><tr><td align="left" rowspan="1" colspan="1">Cell size</td><td align="left" rowspan="1" colspan="1">14&#x02013;23 &#x003bc;m</td></tr><tr><td align="left" rowspan="1" colspan="1">Population doubling time</td><td align="left" rowspan="1" colspan="1">8.25 hours</td></tr><tr><td align="left" rowspan="1" colspan="1">Viability</td><td align="left" rowspan="1" colspan="1">96%</td></tr><tr><td align="left" rowspan="1" colspan="1">Fetal age</td><td align="left" rowspan="1" colspan="1">12 weeks</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec010"><title>Animal experiment</title><p>A comprehensive description of the protocol is also available at <ext-link ext-link-type="uri" xlink:href="http://www.jove.com/video/51269">http://www.jove.com/video/51269</ext-link>. [<xref rid="pone.0143953.ref007" ref-type="bibr">7</xref>] Female landrace specific pathogen free pigs (n = 19) (van Beek SPF Varkensfokkerij B.V. Lelystad, the Netherlands), weighing 68.5 &#x000b1; 5.4 kg (Upper and lower limit 60.6&#x02013;82.0 kg) at baseline, were pre-treated with amiodaron for 10 days (1200 mg/day for 10 days, 800 mg/day maintenance), clopidogrel for 3 days (75 mg/day) and acetylsalicylic acid for 1 day (320 mg loading dose, 80 mg/day maintenance) and a fentanyl patch (25&#x003bc;g/h) for 1 day. One day before cell or placebo delivery, cyclosporin (CsA) was started. Based on clinical organ transplantation protocol,[<xref rid="pone.0143953.ref008" ref-type="bibr">8</xref>] pigs received a loading dose of 800 mg, then 400 mg b.i.d. for 1 week and 200 mg b.i.d for the remaining 3 weeks by oral administration (Neoral drink, 100mg/ml, Novartis Pharma bv). At the day of surgery, one dosage was i.v. infused as 200 mg in 100mL over 2 hours (Sandimmune 50mg/ml, Novartis Pharma bv). All medication, except for the fentanyl patch, was continued until the end of follow up. Pigs received fiber rich pellets (Abdiets animal nutrition, product 2755, Woerden, The Netherlands) twice a day and water was available ad libitum. Animals were kept fasted the day of surgery (except for medication).</p><p>Anaesthesia was obtained by intramuscular injection of 10 mg/kg ketamine, 0.4 mg/kg midazolam and 0.5 mg/kg atropine in the cage. Pigs were intubated and transported to the operating theatre. Maintenance anaesthesia consisted continues infusion of 0.5 mg/kg/h midazolam, 2.5 &#x003bc;g/kg/h sufentanyl and 0.1 mg/kg/h pancuronium. Other perioperative medication consisted of 300 mg amiodaron, amoxicillin + clavulanic acid 750/75 mg and heparin (100 IE/kg after positioning the sheaths and 50 IE/kg every 2 hours). Pigs were mechanically ventilated with a positive pressure ventilator with FiO2 0.5, 10ml/kg tidal volume and a frequency of 12/minute under continuous capnography. Arterial access was achieved by cannulating the internal carotid artery with an 8F sheath. Venous access was achieved by cannulating the jugular vein with a 9F sheath. An additional arterial line was inserted in a small peripheral artery in the hind limb for continuous stable arterial pressure registration.</p></sec><sec id="sec011"><title>Echocardiography</title><p>Pigs were positioned in the right lateral position. Parasternal short axis images were obtained at 3 levels (mitral valve, papillary muscle and apex) during 5 beats per level (iE33 ultrasound device Philips, Eindhoven, The Netherlands). Short axis images were analysed offline using Xcelera R2.L1 (Philips Healthcare, Best, The Netherlands) and fractional area shortening (FAS), fractional shortening (FS) and septal wall thickening (WTsept) at the level of the mitral valve, papillary muscle and apex (mitral, pap, apex respectively) were calculated. Because of apical dilatation of the left ventricle after infarct, the modified Simpsons rule was not applicable and no reliable volumes could be calculated.</p><sec id="sec012"><title>Pressure volume loop measurement</title><p>Admittance based PV-loop measurements were performed as recently described. [<xref rid="pone.0143953.ref009" ref-type="bibr">9</xref>] Cardiac output (CO) was measured three times by thermodilution and stroke volume was calculated out of three measurements. The 7F tetra-polar admittance catheter (7.0 VSL Pigtail/no lumen, Transonic Scisense, London, Canada) was inserted into the left ventricle through the arterial sheath under fluoroscopic guidance. Inferior caval vein occlusion was performed using an 8F Fogarty occlusion catheter (62080814F, Edwards Lifesciences). All measurements were performed during apnea. Data were offline analysed using Iworx analysis software (Labscribe V2.0).</p></sec></sec><sec id="sec013"><title>Intracoronary pressure and flow velocity assessment</title><p>Intracoronary pressure and flow were assessed by positioning a Combowire in the left anterior descending artery (LAD) and the left circumflex coronary artery (LCX) acting as a control subsequently. Intracoronary pressure and flow measurements, together with arterial pressure and ECG, were recorded using the ComboMap system (Volcano Corporation). An intracoronary bolus of 200 &#x003bc;g nitroglycerin was administered to prevent coronary spasms. Three successive measurements were recorded in rest and during hyperaemia, achieved by intracoronary administration of 60 &#x003bc;g adenosine. Data were analysed offline, using AMC Volcano Studymanager (versus 6.0, Borland Software Corporation and Delphi versus 2010, Embarcadero, San Francisco, CA, USA).</p></sec><sec id="sec014"><title>Ischemia/reperfusion injury</title><p>After baseline measurements, the diameter of the LAD, distal to the second diagonal branch (D2) was measured in anterior-posterior and left anterior oblique 30&#x000b0; view. Before positioning the balloon, an intracardiac defibrillation catheter was placed in the right ventricle. A PCI-balloon catheter with a suitable diameter was positioned distal from the D2 and inflated for 90 minutes. In case of ventricular arrhythmias, chest compressions were started immediately, amiodaron 300mg was infused intravenously and pigs were defibrillated intracardiac with 50J. In case of multiple unsuccessful shocks, defibrillation was switched to transthoracic defibrillation with 150-200J.</p></sec><sec id="sec015"><title>Cell infusion</title><p>Ten million cells were resuspended in 10mL of phosphate buffered saline (PBS), one hour before intracoronary infusion. Cell suspension or placebo (10mL of PBS) was handed to the animal technician in a covered sterile syringe so that the personnel at the operating theatre remained blinded for the treatment allocation. An over-the-wire PCI balloon catheter (Apex, Boston Scientific), was positioned distal to the D2, according to the position of the PCI catheter during infarct creation. The balloon was inflated until pressure matched the coronary diameter. 10mL of cell suspension or placebo was infused in three sessions consisting of 30 seconds infusion of 3.3mL during 2 minutes balloon occlusion followed by 3 minutes of reperfusion. Intracoronary pressure and flow measurements were repeated, 30 minutes after the last reperfusion period, to detect possible flow restrictions caused by cell or placebo infusion.</p></sec><sec id="sec016"><title>MRI</title><p>At the end of follow up, cardiac MRI and all other functional measurements were performed. All MR studies were performed on a 3T MRI scanner (Achieva TX, software release 3.2; Philips Healthcare, Best, The Netherlands). Both cine images and LGE images in short axis and a two-chamber long axis orientations were obtained under continuous anesthesia and mechanical ventilation. LGE images were obtained at least 15 minutes after injection of 0.2 ml/kg gadobutrol (Gadovist, Bayer Healthcare). Offline imaging analysis for functional measurements was performed in Qmass MR 7.4 enterprise solutions (Medis medical imaging systems BV, Leiden) and by Segment version v1.9R 3293 (Medviso AB, Lund, Sweden) for infarct size. Infarct size at the end of follow-up was analysed based on the 2SD method.</p></sec><sec id="sec017"><title>Infarct size</title><p>Animals were sacrificed by exsanguination under general anesthesia. The hearts were excised, washed and cooled with running tap water and the LV was then cut into 5 equal slices from apex to base. Slices were incubated in 1% TTC (Sigma-Aldrich Chemicals, Zwijndrecht, the Netherlands) in 37&#x000b0;C 0.9%NaCl for 15 min to discriminate infarcted tissue from viable myocardium. The infarcted area was calculated as percentage of the left ventricle.</p></sec><sec id="sec018"><title>Histology</title><p>Sections of infarct zone, border zone and remote area of all pigs were isolated and fixated in 4% formalin for at least 1 week and then embedded in paraffin. Sections of 5 &#x003bc;m were stained for endothelial cells by lectin (Lectin fom Bandeiraea simplicifolia, Sigma Aldrich L5391) and for fibrosis by picrosirius red (Sirius red F3B, BDH and picrin acid, Boom. Cat. 12388).</p><p>For vascular density, 5 random pictures per slide with 40x magnification were taken from the border zone area. The number of vessels was counted manually by two independent observers (S.J. and J.G.) and the absolute number of lectin positive vessels per field were averaged. For assessment of fibrosis, 3 random pictures per slide (slides for infarct zone, border zone and remote area) were taken using polarized light during one session. Pictures were analysed in Cell^p (version 5.0 Olympus) for mean grey value and percentage of fibrotic area by using the same settings for all slides.</p></sec><sec id="sec019"><title>Cyclosporin assay</title><p>The effect of CsA on the cells was tested by a migration assay, sprouting matrigel assay and by testing cellular growth factor release.</p><p>Based on the pig serum levels of CsA, in vitro assays were executed to analyze performance of CMPCs in presence of CsA. CMPCs were maintained in 0.1% gelatin coated plates with standard CMPC culture medium. For all in vitro experiments low passages were used (passage 8&#x02013;15). For all assays, standard culture medium was used as a negative control. Three different concentrations of CsA were used as experimental conditions (50 ng/mL, 150 ng/mL and 300 ng/mL). See <xref rid="pone.0143953.s005" ref-type="supplementary-material">S1 File</xref> for detailed description of the methods.</p></sec><sec id="sec020"><title>QPCR</title><p>Genomic DNA was isolated from 1cm<sup>3</sup> cryosections of cardiac tissue from the borderzone area using the Genomed Jetquick tissue DNA spin kit (cat no 450250) for each CMPC treated pig. Tissue of a PBS treated pig was also included in the experiment as a control. Furthermore the CMPCs used in our study were analysed as a positive control for human DNA. Samples were analyzed for the presence of human (HLA-DMA) and pig (Pig Gapdh) genomic DNA using the following primers:</p><p>HLA-DMA fwd, <monospace>5&#x02019;-TACAAACCTCAGCTACCTTCGTGGC-3</monospace>
</p><p>HLA-DMA rev, <monospace>5&#x02019;-AACCCAGCTGACTCTGGGTGG-3&#x02019;</monospace>
</p><p>Pig Gapdh fwd, <monospace>5&#x02019;-CCCCCTCAGATTTGGCCGCA-3&#x02019;</monospace>
</p><p>Pig Gapdh rev, <monospace>5&#x02019;-CACGGGGGCCACTCACCAT-3&#x02019;</monospace>
</p><p>After DNA isolation, 250 ng DNA per sample was precipitated, diluted in H2O up to 50 &#x003bc;l and preamplified for 12 cyles using he SsoAdvanced PreAmp Supermix (Biorad 172&#x02013;5160).</p><p>QPCR was performed by adding 9.8 &#x003bc;l SYBR GREEN and 0.2 &#x003bc;l primer (forward and reverse, HLA-DMA and Gapdh) to 10 &#x003bc;l preAMP mix containing 50 ng DNA (denaturation at 95&#x000b0;C; annealing at 61&#x000b0;C; and extension at 72&#x000b0;C). After quantitative PCR, 5 &#x003bc;l of the amplified PCR samples plus 1 &#x003bc;l loading dye were loaded on a 2% agarose gel (5 gram agarose, 250ml Tris-acetate-EDTA buffer).</p></sec><sec id="sec021"><title>Statistical analysis</title><p>Data are reported as mean &#x000b1; standard deviation. Comparisons of serial measurements over time within one group or for all animals combined were performed by paired t-tests. Comparisons between both groups were made by independent t-tests. Differences between conditions in cyclosporin assays were tested by one-way ANOVA.</p><p>The statistical software used is IBM SPSS statistics, version 20.0 (IBM Corporation, Armonk, NY, USA).</p></sec></sec><sec sec-type="results" id="sec022"><title>Results</title><p>A total of 19 pigs were used in this study. In 9 pigs VF occurred during occlusion, of which 8 converted successfully by defibrillation and 1 to 3 intravenous boluses of 150 mg amiodaron infusion. One animal could not be safed by these efforts, despite an additional 0,5 mg adrenaline. A total of three pigs died; one pig died of VF during LAD occlusion, one pig died by periprocedural complications before cell/placebo infusion and one animal died one day after placebo infusion by unknown cause. All other 16 animals were included in this study.</p><sec id="sec023"><title>Safety</title><p>Two hours after cell infusion during short coronary occlusion, high sensitive troponin I (TnI) levels were 545 &#x000b1; 460 ng/L n = 8 after cell infusion and 623 &#x000b1; 764 ng/L n = 8 after placebo infusion. In comparison, mean TnI levels 3.5 hours after the start of 90 minutes balloon occlusion, were 1147822 &#x000b1; 584559 ng/L (n = 16), confirming the induction of a large MI.</p><p>Intracoronary pressure and flow measurement (see below) showed no evidence for intracoronary embolization or obstruction in CMPC treated animals 30 minutes after infusion. None of the CMPC treated animals died by arrhythmias, or any other cause.</p></sec><sec id="sec024"><title>Left ventricular performance</title><sec id="sec025"><title>MRI</title><p>At the end of follow-up EF, EDV and ESV did not differ between groups. EF in CMPC treated animals was 40.6 &#x000b1; 4.2% versus 38.3 &#x000b1; 8.6% in placebo animals (p = 0.52). EDV was 172.7 &#x000b1; 19.0 ml in CMPC treated animals and 150.0 &#x000b1; 27.1 ml in placebo (p = 0.07). ESV was 102.6 &#x000b1; 13.3 ml in CMPC treated and 91.5 &#x000b1; 14.9 ml in placebo animals (p = 0.14). (<xref rid="pone.0143953.g002" ref-type="fig">Fig 2</xref>)</p><fig id="pone.0143953.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0143953.g002</object-id><label>Fig 2</label><caption><title>Functional measurements by MRI of cell- and placebo treated animals at follow up.</title><p>Individual data and mean with SD, n = 8 per group. EF Left ventricular ejection fraction, EDV End diastolic volume, ESV End systolic volume.</p></caption><graphic xlink:href="pone.0143953.g002"/></fig></sec><sec id="sec026"><title>PV-loop</title><p>Serial functional measurements were performed by PV-loop. Because of technical failure, we could not complete data analysis of all animals at all time points. For EF, ESV and EDV we could include 7 out of 8 cell treated animals and all 8 placebo animals. For end systolic pressures volume relationship (ESPVR), end diastolic pressure volume relationship (EDPVR) and V0, we could include 6 animals per group.</p><p>Induction of MI caused a significant decrease in EF over 4 weeks (-8.7 &#x000b1; 11.6% from 54.8 &#x000b1; 8.7 to 46.1 &#x000b1; 9.5 p = 0.01) and an increase in ESV (+40.6 &#x000b1; 62.3 ml from 85.3 &#x000b1; 27.1 to 125.9 &#x000b1; 49.1 p = 0.02), and trend towards an increased EDV (+38.1 &#x000b1; 73.6 ml, from 186.7 &#x000b1; 37.6 ml to 224.7 &#x000b1; 50.9 p = 0.07), confirming successful creation of a chronic MI model. No significant differences between both groups were observed at pre-infusion time point (EF p = 0.34, EDV p = 0.40, ESV p = 0.27). (<xref rid="pone.0143953.g003" ref-type="fig">Fig 3</xref>)</p><fig id="pone.0143953.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0143953.g003</object-id><label>Fig 3</label><caption><title>Functional outcome measurements by PV loop.</title><p>Mean and SD for PVloop parameters. EDV End diastolic volume, ESV End systolic volume, EF Left ventricular ejection fraction, ESPVR End systolic pressures volume relationship, EDPVR end diastolic pressure volume relationship. Placebo n = 8, cell n = 7 for ESV, EDV and EF, n = 6 per group for ESPVR, EDPVR and V0.</p></caption><graphic xlink:href="pone.0143953.g003"/></fig><p>For all parameters (EDV, ESV, EF, ESPVR, EDPVR and V0), no differences between both groups were found at any time point except for EDPVR at follow up. EDPVR was 0.004 &#x000b1; 0.002 for cell treated animals and 0.008 &#x000b1; 0.004 for placebo animals (p = 0.04). Visual appearing trends in functional outcomes are observed in <xref rid="pone.0143953.g003" ref-type="fig">Fig 3</xref> (and <xref rid="pone.0143953.s007" ref-type="supplementary-material">S2 Table</xref>). However, EF did not increase after cell or placebo infusion (p = 0.85 and p = 0.17 respectively) EDV and ESV did not change after cell treatment (p = 0.25 and p = 0.58 respectively), but both significantly increased after placebo infusion (p = 0.01 and p = 0.004), suggesting further deterioration after placebo infusion compared to cell treatment. No statistical significant differences in &#x00394;EDV and &#x00394;ESV were found between cell treated animals and placebo animals.</p></sec><sec id="sec027"><title>Echocardiography</title><p>
<xref rid="pone.0143953.s010" ref-type="supplementary-material">S1</xref> and <xref rid="pone.0143953.s011" ref-type="supplementary-material">S2</xref> Videos show representative long and short axis echocardiography images.</p><p>WTsept and FAS at the apical level significantly decreased after MI (WTsept -0.34 &#x000b1; 0.23 p &#x0003c; 0.001, FAS -0.08 &#x000b1; 0.11 p = 0.02), confirming successful apical infarct creation. A trend towards decrease of FS at the apical level was also observed (-0.50 &#x000b1; 0.11 p = 0.08) in both groups.</p><p>For FAS, FS and WTsept, no statistical significant differences were identified between groups at any time point. A trend was observed for a higher mean FAS (mean of three levels) at follow up in cell treated animals compared to placebo animals (cell treated 0.49 &#x000b1; 0.06 placebo 0.44 &#x000b1; 0.04 p = 0.08). Next, no differences in decrease or increase of any other echocardiographic parameter after hCMPC or placebo infusion was observed. (<xref rid="pone.0143953.g004" ref-type="fig">Fig 4</xref> and <xref rid="pone.0143953.s008" ref-type="supplementary-material">S3 Table</xref>)</p><fig id="pone.0143953.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0143953.g004</object-id><label>Fig 4</label><caption><title>Functional measurements by echocardiography.</title><p>Mean and SD, n = 8 per group. FAS Fractional area shortening, FS Fractional shortening, sWT Septal wall thickening at the level of the apex.</p></caption><graphic xlink:href="pone.0143953.g004"/></fig></sec></sec><sec id="sec028"><title>Intracoronary pressure and flow</title><p>Hyperemic microvascular resistance is a parameter for assessing the microvascular bed and is calculated as the ratio of intracoronary pressure (Pd) and hyperemic average peak flow velocity (pAPV). It is known from previous studies that HMR increases after I/R, accompanied by decreased pAPV and a constant Pd.[<xref rid="pone.0143953.ref010" ref-type="bibr">10</xref>] At the time point of cell infusion, measurements in one animal failed because of technical problems.</p><p>HMR in the LAD region significantly increased after I/R as expected (p = 0.03), Pd in the LAD significantly increased (p = 0.03) and pAPV in the LAD tended towards a decrease of (p = 0.10). All parameters in the control region remained stable over time. Thirty minutes after cell or placebo infusion, HMR was significantly decreased in all animals (2.7 &#x000b1; 1.0 mmHg/cm/s pre-infusion, 2.2 &#x000b1; 0.6 mmHg/cm/s post-infusion, p = &#x0003c;0.001), without any differences between hCMPC and placebo treated animals (&#x00394;HMR -0.50 &#x000b1; 0.48 mmHg/cm/s for hCMPC treated, -0.56 &#x000b1; 0.66 mmHg/cm/s for placebo treated animals, p = 0.21). Decrease in HMR was accompanied by an increase in pAPV (41.5 &#x000b1; 11.0 cm/s pre-infusion, 48.9 &#x000b1; 11.7 post-infusion, p = 0.01), without differences between groups (p = 0.7), both advocating against intracoronary (micro-)embolization or obstruction by cell infusion. Decreased HMR and increased pAPV can be explained as a hyperemic response after short ischemia during infusion. Neither cell-, nor placebo infusion caused a change in microvascular parameters over time.</p></sec><sec id="sec029"><title>Infarct size</title><p>For LGE, infarct size was 17.5 &#x000b1; 3.8% and 18.0 &#x000b1; 4.5% of the left ventricular mass for cell treated and placebo animals respectively at follow up. For TTC, infarct size in the cell treated group was 14.6 &#x000b1; 2.5% of the left ventricle, and 13.8 &#x000b1; 3.9 in the control group. There was no statistical difference in infarct size between both groups at termination of follow-up, for both modalities. (<xref rid="pone.0143953.g005" ref-type="fig">Fig 5</xref>)</p><fig id="pone.0143953.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0143953.g005</object-id><label>Fig 5</label><caption><title>Infarct size.</title><p>Representative pictures of TTC stained heart slice and LGE image of the same animal. Mean (&#x000b1;SD) infarct size of CMPC and placebo animals were 14.6 &#x000b1; 2,5% and 13.8 &#x000b1; 3.9% of the left ventricle based on TTC staining and 17.5 &#x000b1; 3.8 and 18.0 &#x000b1; 4.5 based on LGE imaging.</p></caption><graphic xlink:href="pone.0143953.g005"/></fig></sec><sec id="sec030"><title>Histology</title><p>For fibrosis, there were no differences between both groups. A significant higher vascular density was observed in the placebo group compared to the hCMPC animals. (<xref rid="pone.0143953.t002" ref-type="table">Table 2</xref>, Figs <xref rid="pone.0143953.g006" ref-type="fig">6</xref> and <xref rid="pone.0143953.g007" ref-type="fig">7</xref>)</p><table-wrap id="pone.0143953.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0143953.t002</object-id><label>Table 2</label><caption><title>Fibrosis.</title></caption><alternatives><graphic id="pone.0143953.t002g" xlink:href="pone.0143953.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">CMPC (n = 8)</th><th align="center" rowspan="1" colspan="1">Placebo (n = 8)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">% Fibrosis</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Infarct</td><td align="center" rowspan="1" colspan="1">39.1 &#x000b1; 12.2</td><td align="center" rowspan="1" colspan="1">40.0 &#x000b1; 16.0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Border</td><td align="center" rowspan="1" colspan="1">1.6 &#x000b1; 1.2</td><td align="center" rowspan="1" colspan="1">2.9 &#x000b1; 2.3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Remote</td><td align="center" rowspan="1" colspan="1">6.5 &#x000b1; 7.8</td><td align="center" rowspan="1" colspan="1">2.8 &#x000b1; 2.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Grey value</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Infarct</td><td align="center" rowspan="1" colspan="1">27.0 &#x000b1; 8.9</td><td align="center" rowspan="1" colspan="1">28.5 &#x000b1; 12.7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Border</td><td align="center" rowspan="1" colspan="1">1.2 &#x000b1; 0.7</td><td align="center" rowspan="1" colspan="1">2.0 &#x000b1; 1.4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Remote</td><td align="center" rowspan="1" colspan="1">4.3 &#x000b1; 4.3</td><td align="center" rowspan="1" colspan="1">2.6 &#x000b1; 2.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular density</td><td align="center" rowspan="1" colspan="1">33.9 &#x000b1; 10.1</td><td align="center" rowspan="1" colspan="1">48.3 &#x000b1; 10.1 <xref rid="t002fn001" ref-type="table-fn">*</xref>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>* p = 0.01 between CMPC and placebo.</p></fn></table-wrap-foot></table-wrap><fig id="pone.0143953.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0143953.g006</object-id><label>Fig 6</label><caption><title>Fibrosis.</title><p>Representative picture of a picrosirius red stained borderzone slide (A. bright field, B. polarized light) and a higher magnification of a picrosirius red stained slides isolated from the infarct area (C,D), borderzone (E,F) and remote area (G,H) of the left ventricle (bright field C,E,G, polarized light (D,F,H).</p></caption><graphic xlink:href="pone.0143953.g006"/></fig><fig id="pone.0143953.g007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0143953.g007</object-id><label>Fig 7</label><caption><title>Vascular density.</title><p>Respresentative picutures of Lectin staining of the borderzone of a CMCP treated animals (A) and a placebo animal (B)</p></caption><graphic xlink:href="pone.0143953.g007"/></fig></sec><sec id="sec031"><title>Cyclosporin</title><p>Mean CsA levels at follow up per animal is provided in <xref rid="pone.0143953.s009" ref-type="supplementary-material">S4 Table</xref>. <italic>In vitro</italic> assays showed that CsA did not affect functioning of CMPCs with regard to migration capacity, angiogenesis and growth factor secretion. See <xref rid="pone.0143953.s005" ref-type="supplementary-material">S1 File</xref> and <xref rid="pone.0143953.s002" ref-type="supplementary-material">S2</xref>&#x02013;<xref rid="pone.0143953.s004" ref-type="supplementary-material">S4</xref> Figs for supporting information and the results of the <italic>in vitro</italic> assays.</p></sec><sec id="sec032"><title>QPCR</title><p>Quantitative PCR showed absence of human DNA in all pig tissue samples. HLA was successfully amplified in the positive control (samples containing fhCMPCs). Pig DNA (Gapdh) was present in all samples containing pig tissue. Blotting of the samples after running them on gel confirmed absence of human material in the pig tissue samples. (<xref rid="pone.0143953.g008" ref-type="fig">Fig 8</xref>)</p><fig id="pone.0143953.g008" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0143953.g008</object-id><label>Fig 8</label><caption><title>QPCR.</title><p>A. QPCR shows presence of genomic pig DNA (Gapdh) in all pig tissues treated with CMPC or placebo and absence of pig DNA in the sample containing human CMPCs (Human) and the negative control (Neg) containing H2O used for PCR. B. Human genomic DNA (HLA-DMA) was detected in the sample containing human CMPCs (Human), but was absent in all the pig tissues (CMPC and Placebo) and the negative control (Neg) containing H2O used for PCR</p></caption><graphic xlink:href="pone.0143953.g008"/></fig></sec></sec><sec sec-type="conclusions" id="sec033"><title>Discussion</title><p>In this pre-clinical model of chronic MI, we show that xenotransplantation via intracoronary infusion of fetal hCMPCs is feasible and safe, but we did not find a benefit in the current model on cardiac function, infarct size, fibrosis and vascular density. The non-significant difference in EF between both groups of 2.3% measured by the golden standard MRI is lower than the effect size of 7.5% as documented in a recent meta-analysis and used for power calculation.</p><p>We believe that these data in the field of cardiac regeneration are of great importance. It complements the preclinical evidence needed for successful translation of cardiac regeneration by cardiac cell therapy from bench to bedside. We present a solid and sound piece of evidence since this study is conducted by clinical standards in terms of blinding, randomization and outcome assessment.</p><sec id="sec034"><title>Preclinical studies of cardiac cell therapy</title><p>The neutral results presented in the current study, are partly in line with other large animal studies with cardiac stem cells for MI (<xref rid="pone.0143953.t003" ref-type="table">Table 3</xref>). Over the last decade, five different cardiac stem cell sources have been identified[<xref rid="pone.0143953.ref011" ref-type="bibr">11</xref>] and two of them have been extensively tested in large animal studies. Clonogenic, multipotent and self-renewing cardiac stem cells, based on the C-kit epitope (CSCs)[<xref rid="pone.0143953.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0143953.ref013" ref-type="bibr">13</xref>] and cluster-forming cells, positive for C-kit and Sca-1, called cardiosphere derived cells (CDCs) [<xref rid="pone.0143953.ref014" ref-type="bibr">14</xref>] were used in these studies. Both cell types have gone through the process of pre-clinical investigation and progressed from bench to bedside testing. In a recent study, expanded cells upon different cardiac progenitor cell isolation procedures were compared (including, c-kit+, cardiospheres, and sca1+ cells), and it was suggested that these cells have highly similar transcriptional profiles.[<xref rid="pone.0143953.ref015" ref-type="bibr">15</xref>] Therefore, it is important to closely look at particular study design aspects of the study to look for possible explanations</p><table-wrap id="pone.0143953.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0143953.t003</object-id><label>Table 3</label><caption><title>Overview of studies of cardiac derived stem cells in pig models.</title></caption><alternatives><graphic id="pone.0143953.t003g" xlink:href="pone.0143953.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">Route</th><th align="center" rowspan="1" colspan="1">Source</th><th align="center" rowspan="1" colspan="1">Immuno suppression</th><th align="center" rowspan="1" colspan="1">Dose</th><th align="center" rowspan="1" colspan="1">Timing</th><th align="center" rowspan="1" colspan="1">Follow up</th><th align="center" rowspan="1" colspan="1">Result</th></tr></thead><tbody><tr><td colspan="9" align="left" rowspan="1">
<bold>CDC</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Johnston et al. Circulation 2009</bold> [<xref rid="pone.0143953.ref017" ref-type="bibr">17</xref>]</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">IC</td><td align="center" rowspan="1" colspan="1">Autologous</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">1,0E+07</td><td align="center" rowspan="1" colspan="1">4 wk</td><td align="center" rowspan="1" colspan="1">8 wk</td><td align="center" rowspan="1" colspan="1">No EF or IS improvement</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lee et al. JACC 2011</bold> [<xref rid="pone.0143953.ref018" ref-type="bibr">18</xref>]</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">IM</td><td align="center" rowspan="1" colspan="1">Autologous</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">1,0E+07</td><td align="center" rowspan="1" colspan="1">4 wk</td><td align="center" rowspan="1" colspan="1">8 wk</td><td align="center" rowspan="1" colspan="1">No functional improvement on echo. EF improved on LV angiography</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Malliaras et al. Circulation 2013</bold> [<xref rid="pone.0143953.ref019" ref-type="bibr">19</xref>]</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">IC</td><td align="center" rowspan="1" colspan="1">Allogeneic</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">1,25E+07</td><td align="center" rowspan="1" colspan="1">2&#x02013;3 wk</td><td align="center" rowspan="1" colspan="1">8 wk</td><td align="center" rowspan="1" colspan="1">EF preservation, IS reduction</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Kanazawa et al.</bold>[<xref rid="pone.0143953.ref020" ref-type="bibr">20</xref>] <bold>Circ. Heart Fail. 2015</bold>
</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">IC</td><td align="center" rowspan="1" colspan="1">Allogeneic</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">8,5-9E+06</td><td align="center" rowspan="1" colspan="1">30 mins</td><td align="center" rowspan="1" colspan="1">2 days</td><td align="center" rowspan="1" colspan="1">No difference in EF, IS reduction</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yee et al</bold>. <xref rid="t003fn002" ref-type="table-fn">*</xref>[<xref rid="pone.0143953.ref021" ref-type="bibr">21</xref>] <bold>PLoS ONE 2014</bold>
</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">TE</td><td align="center" rowspan="1" colspan="1">Allogeneic</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">1,5E+08</td><td align="center" rowspan="1" colspan="1">8 wk</td><td align="center" rowspan="1" colspan="1">8 wk</td><td align="center" rowspan="1" colspan="1">No functional improvement, IS reduction</td></tr><tr><td colspan="9" align="left" rowspan="1">
<bold>CSC</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Williams et al. Circulation 2013</bold> [<xref rid="pone.0143953.ref022" ref-type="bibr">22</xref>]</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">IM</td><td align="center" rowspan="1" colspan="1">Human</td><td align="center" rowspan="1" colspan="1">Cyclosporin</td><td align="center" rowspan="1" colspan="1">1,0E+06</td><td align="center" rowspan="1" colspan="1">14 days</td><td align="center" rowspan="1" colspan="1">1 mnth</td><td align="center" rowspan="1" colspan="1">Restored EF, IS reduction</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Bolli et al. Circulation 2013</bold> [<xref rid="pone.0143953.ref023" ref-type="bibr">23</xref>]</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">IC</td><td align="center" rowspan="1" colspan="1">Autologous</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">5,0E+05</td><td align="center" rowspan="1" colspan="1">3&#x02013;4 mnth</td><td align="center" rowspan="1" colspan="1">1 mnth</td><td align="center" rowspan="1" colspan="1">Improved EF, IS reduction</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>IM intramyocardial injections, IC intracoronary infusion, TE transendocardial injections, EF ejection fraction, IS infarct size.</p></fn><fn id="t003fn002"><p>* used cardiospheres instead of CDCs.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec035"><title>Study design considerations</title><p>A multitude of parameters in the research field of cell therapy for cardiac repair must be considered when conducting pre-clinical or clinical studies, like timing of therapy, administration route, cell source, cell number, etc. In a meta-analysis including all large animal studies on cell therapy for MI, none of these parameters showed significant impact on effect size.[<xref rid="pone.0143953.ref016" ref-type="bibr">16</xref>] Additionally, no ruling about these issues was provided based on previous CSC studies (<xref rid="pone.0143953.t003" ref-type="table">Table 3</xref>). Therefore, we made upfront decisions about all these variables based on experience and clinical relevance.</p><p>Treatment of acute myocardial infarction is greatly improved over the last decades, but patients surviving the initial episode often suffer from chronic ischemic heart failure. The current animal model was designed to represent this group. A direct comparison of efficacy of stem cells in acute versus chronic ischemic heart disease has never been performed, but safety is at least similar in acute and chronic patients.[<xref rid="pone.0143953.ref024" ref-type="bibr">24</xref>] <xref rid="pone.0143953.t003" ref-type="table">Table 3</xref> shows negative and positive results of cardiac cell therapy in both acute and chronic settings.</p><p>We administered cells via intracoronary infusion, which is considered as efficient as other routes with regard to cell retention [<xref rid="pone.0143953.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0143953.ref027" ref-type="bibr">27</xref>] and functional improvement [<xref rid="pone.0143953.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0143953.ref029" ref-type="bibr">29</xref>] but is less invasive then intramyocardial injections and less time consuming compared to transendocardial delivery.</p><p>We investigated efficacy of infusion of 10 million cells. <xref rid="pone.0143953.t003" ref-type="table">Table 3</xref> show both positive and neutral results from CDCs in comparable doses. For CSCs, promising results are found by infusion of 0.5 and 1 million cells in smaller pigs (1.5 &#x000b1; 0.8kg and 35&#x02013;40 kg respectively, compared to 68.5 &#x000b1; 5.4 kg in the current study).[<xref rid="pone.0143953.ref022" ref-type="bibr">22</xref>,<xref rid="pone.0143953.ref023" ref-type="bibr">23</xref>] Roughly, we applied 4 times higher indexed doses (37.000/kg versus 140.000/kg) of cells. These data show that relative under-dosing was certainly not anticipated for in the present study.</p></sec><sec id="sec036"><title>Xenogenicity</title><p>The impact of xenogenicity is important since human cells were administered in a porcine model. Alloreactivity (and xenoreactivity) depends on foreign peptide presentation by the major histocompatibility complex (MHC) on antigen presenting cells and detection by T cells.[<xref rid="pone.0143953.ref030" ref-type="bibr">30</xref>] In clinical practice, alloreactivity is suppressed by T cell suppressors like CsA, and this strategy was applied accordingly in the present study.</p><p>Next to immunosuppression, the effect of CsA includes prevention of apoptosis [<xref rid="pone.0143953.ref031" ref-type="bibr">31</xref>] and protection of the myocardium in the setting of acute myocardial infarction.[<xref rid="pone.0143953.ref032" ref-type="bibr">32</xref>]. Since CsA was administered at 4 weeks after MI until the end of follow-up, we believe it did not affect the outcome by that cause. Adequate dosing by oral administration of CsA is safe in pigs[<xref rid="pone.0143953.ref033" ref-type="bibr">33</xref>], but not much is known about the pharmacodynamics. We did not observe differences in serum levels of leukocytes, nor on renal function between hCMPC and placebo treated animals 30 minutes and 4 weeks after treatment, all receiving CsA. Also, we did not find a correlation between serum CsA levels at follow up and effect size.</p><p>There is no consensus about the effect of CsA on stem cells <italic>in vitro</italic> and <italic>in vivo</italic>.[<xref rid="pone.0143953.ref033" ref-type="bibr">33</xref>] In this respect, we tested the effect of different levels of CsA on migration, angiogenesis and growth factor expression of hCMPCs <italic>in vitro</italic> (See <xref rid="pone.0143953.s005" ref-type="supplementary-material">S1 File</xref>). No significant effect of CsA was noted. Taken together, we assume that our results are not confounded by the chosen CsA regimen.</p><p>Despite adequate immunosuppression, we anticipated on low cell retention rates. Based on a study by our own lab, and several other studies, we know that short term cell retention is around 10&#x02013;15% irrespective of the administration route.[<xref rid="pone.0143953.ref017" ref-type="bibr">17</xref>&#x02013;<xref rid="pone.0143953.ref019" ref-type="bibr">19</xref>] Long term cell retention is expected to be even lower. Despite these discouraging numbers, administration of cells does improve cardiac function in almost all clinical and preclinical studies.[<xref rid="pone.0143953.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0143953.ref034" ref-type="bibr">34</xref>] This supports the proposed working mechanism by endogenous signaling and the redundancy of (long-term) cell retention to establish effect.[<xref rid="pone.0143953.ref035" ref-type="bibr">35</xref>,<xref rid="pone.0143953.ref036" ref-type="bibr">36</xref>] As anticipated, no human cells could be traced in the small pieces of tissue that we collected from the borderzone area of the pig hearts 4 weeks after therapy. However, presence of human cells in the rest of the heart cannot be excluded with complete certainty.</p></sec><sec id="sec037"><title>Internal and external validity</title><p>Internal validity has major impact on effect size, as it is known that blinded and randomized studies produce smaller effect sizes compared to non-blinded and non-randomized reports.[<xref rid="pone.0143953.ref037" ref-type="bibr">37</xref>] Based on clinical standards, our pre-clinical study has been performed in a randomized, blinded (both for intervention and outcome assessment) and placebo-controlled manner.</p><p>The animal model is a surrogate for human disease. We included large pigs (68.5 &#x000b1; 5.4 kg), as the heart corresponds with human (coronary) anatomy and size, to increase external validity (the translatability towards other models or populations). However, age and co-morbidity are not accounted for in this model.</p></sec><sec id="sec038"><title>Preclinical studies of non-cardiac cell therapy for cardiac regeneration</title><p>Next to cardiac tissue derived cell types, embryonic stem cell derived- and induced pluripotent derived cardiomyocytes (ESC-CMs and IPCS-CMc) may hold promise for cardiac regenerative therapy. The first results of transplantation of human ESC-CMs in a large animal model of non-human primates are promising since hESC-CMs showed to remuscularize the heart.[<xref rid="pone.0143953.ref038" ref-type="bibr">38</xref>] In the four treated animals, grafts are vascularized and electromechanically coupled. The major drawback of this this small open-label non-randomized study is the observed ventricular arrhythmias. Next, transplantation of human IPSC-CMs combined with IPCS derived endothelial cells and smooth muscle cells into the myocardium of a porcine model of acute MI shows engraftment of cells and development into functioning cardiomyocytes accompanied by improvement of left ventricular function and infarct size.[<xref rid="pone.0143953.ref039" ref-type="bibr">39</xref>]</p><p>These two studies show the potential of non-cardiac derived cardiac-cell therapy. Further investigation of cardiac regeneration by these cell sources is needed for safe and successful clinical translation.</p><p>Our standardized way of infarct creation caused a decrease in EF of 8.7% based on PV-loop measurements, despite high TnI levels and a mean infarct size of 17.8%. It is known from clinical studies that patients with a low baseline EF benefit most from cell therapy.[<xref rid="pone.0143953.ref040" ref-type="bibr">40</xref>,<xref rid="pone.0143953.ref041" ref-type="bibr">41</xref>] In retrospect, the anticipated effect size of 7.5% (difference in EF at follow up between cell and placebo treated animals on MRI) might have been too high. Power calculation was based on difference in EF at follow up, measured by MRI and not for the other functional measurement modalities (echocardiography and PV-loop), which might thereby be underpowered to report significant differences.</p><p>Finally it has to be acknowledged that the Sca-1 antigen (stem cell antigen 1) is well characterized in mice. In 2003 cardiac stem cells were isolated from mouse hearts using anti-sca-1 antibodies. These cells showed to be multipotent and self-renewing.[<xref rid="pone.0143953.ref042" ref-type="bibr">42</xref>] Although the human equivalent of the Sca-1 epitope is unknown, anti-Sca-1 antibodies are successfully used to reproducibly isolate stem cells from fetal and adult human hearts.[<xref rid="pone.0143953.ref004" ref-type="bibr">4</xref>] These cells express Isl-1, C-kit, CD31, GATA-4 and Nkx2.5, but no cActin and cTroponin and were therefore called cardiomyocyte progenitor cells.[<xref rid="pone.0143953.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0143953.ref004" ref-type="bibr">4</xref>,] Furthermore, despite different isolation procedures, CMPCs turned out to share high similarity in gene expression profiles with other cardiac cell lines including CSCs and cardiosphere derived cells.[<xref rid="pone.0143953.ref015" ref-type="bibr">15</xref>]</p></sec></sec><sec sec-type="conclusions" id="sec039"><title>Conclusion</title><p>In this randomized, blinded placebo controlled preclinical study, xenotransplantation via intracoronary infusion of fetal human CMPCs in a pig model of chronic I/R injury appeared to be feasible and safe, but showed no significant improvement with regard to cardiac function or infarct size.</p></sec><sec sec-type="supplementary-material" id="sec040"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0143953.s001"><label>S1 Fig</label><caption><title>fhCMPCs in culture.</title><p>fhCMPCs in culture, attached to the survace (A.) and in suspension (B.)</p><p>(TIF)</p></caption><media xlink:href="pone.0143953.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0143953.s002"><label>S2 Fig</label><caption><title>Quantification of cell migration.</title><p>(TIF)</p></caption><media xlink:href="pone.0143953.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0143953.s003"><label>S3 Fig</label><caption><title>Sprouting matrigel assay.</title><p>A. bar plot of angiogenesis parameters. B. representative pictures of matrigel assays for all 4 conditions.</p><p>(TIF)</p></caption><media xlink:href="pone.0143953.s003.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0143953.s004"><label>S4 Fig</label><caption><title>Array map and pictures of the array of 4 conditions at three different intensities.</title><p>Positive control meaning different cell line without Cyclosporin</p><p>(TIFF)</p></caption><media xlink:href="pone.0143953.s004.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0143953.s005"><label>S1 File</label><caption><title>Supporting information.</title><p>(DOC)</p></caption><media xlink:href="pone.0143953.s005.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0143953.s006"><label>S1 Table</label><caption><title>Angiogenesis.</title><p>(DOCX)</p></caption><media xlink:href="pone.0143953.s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0143953.s007"><label>S2 Table</label><caption><title>Functional outcome measured by PV loop.</title><p>EDV End diastolic volume, ESV End systolic volume, EF Left ventricular ejection fraction, SW Stroke work, ESPRV End systolic pressure volume relationship, EDPVR End diastolic pressure volume relationship, dPdT+ maximum pressure rise, dPdT- Minimum pressure rise, V0 Theoretical volume at zero pressure. * p = 0.03 Cell treated animals compared to placebo. For EDV, ESV and EF n = 7 for cell treated animals, n = 8 for placebo treated animals. For SW, ESPRV, EDPVR, dPdT+, dPdT-, V0 and Tau n = 6 per group.</p><p>(DOCX)</p></caption><media xlink:href="pone.0143953.s007.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0143953.s008"><label>S3 Table</label><caption><title>Functional outcomes measured by echocardiography.</title><p>sWT Septal wall thickening, FS Fractional shortening, FAS Fractional area shortening at levels of the mitral valve (mitral) papillary muscle (pap), apex and mean of three levels (mean). N = 8 per group. *p = 0.08 for cell treated animals compared to placebo.</p><p>(DOCX)</p></caption><media xlink:href="pone.0143953.s008.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0143953.s009"><label>S4 Table</label><caption><title>Individual Ciclosporin levels at end of follow up.</title><p>(DOCX)</p></caption><media xlink:href="pone.0143953.s009.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0143953.s010"><label>S1 Video</label><caption><title>Long axis echocardiography.</title><p>Representative long axis view echocardiography, 4 weeks after myocardial infaction (MI), right before CMPC/placebo infusion. Thinning and akinesia of the septal apical wall due to MI can be appreciated.</p><p>(AVI)</p></caption><media xlink:href="pone.0143953.s010.avi"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0143953.s011"><label>S2 Video</label><caption><title>Short axis echocardiography.</title><p>Representative short axis view echocardiography at the level of the apex, 4 weeks after myocardial infaction (MI), right before CMPC/placebo infusion. Thinning and akinesia of the septal wall due to MI can be appreciated.</p><p>(AVI)</p></caption><media xlink:href="pone.0143953.s011.avi"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We kindly thank Corina Metz, Lizanne Bosma, Marlijn Jansen, Joyce Visser, Martijn van Nieuwburg, Grace Croft, Gerard Marchal, Merel Schurink and Evelyn Velema for their excellent technical assistance.</p></ack><ref-list><title>References</title><ref id="pone.0143953.ref001"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Goumans</surname><given-names>M-J</given-names></name>, <name><surname>Maring</surname><given-names>J A</given-names></name>, <name><surname>Smits</surname><given-names>AM</given-names></name> (<year>2014</year>) <article-title>A straightforward guide to the basic science behind cardiovascular cell-based therapies</article-title>. <source>Heart</source>
<volume>100</volume>: <fpage>1153</fpage>&#x02013;<lpage>1157</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/heartjnl-2014-305646">10.1136/heartjnl-2014-305646</ext-link></comment>
<pub-id pub-id-type="pmid">24993501</pub-id></mixed-citation></ref><ref id="pone.0143953.ref002"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Smits</surname><given-names>AM</given-names></name>, <name><surname>van Vliet</surname><given-names>P</given-names></name>, <name><surname>Metz</surname><given-names>CH</given-names></name>, <name><surname>Korfage</surname><given-names>T</given-names></name>, <name><surname>Sluijter</surname><given-names>JP</given-names></name>, <name><surname>Doevendans</surname><given-names>PA</given-names></name>
<etal>et al</etal> (<year>2009</year>) <article-title>Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology</article-title>. <source>Nat Protoc</source>
<volume>4</volume>: <fpage>232</fpage>&#x02013;<lpage>243</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nprot.2008.229">10.1038/nprot.2008.229</ext-link></comment>
<pub-id pub-id-type="pmid">19197267</pub-id></mixed-citation></ref><ref id="pone.0143953.ref003"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Van Vliet</surname><given-names>P</given-names></name>, <name><surname>Smits</surname><given-names>AM</given-names></name>, <name><surname>de Boer</surname><given-names>TP</given-names></name>, <name><surname>Korfage</surname><given-names>TH</given-names></name>, <name><surname>Metz</surname><given-names>CHG</given-names></name>, <name><surname>Roccio</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Foetal and adult cardiomyocyte progenitor cells have different developmental potential</article-title>. <source>J Cell Mol Med</source>
<volume>14</volume>: <fpage>861</fpage>&#x02013;<lpage>870</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1582-4934.2010.01053.x">10.1111/j.1582-4934.2010.01053.x</ext-link></comment>
<pub-id pub-id-type="pmid">20219011</pub-id></mixed-citation></ref><ref id="pone.0143953.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Goumans</surname><given-names>M-J</given-names></name>, <name><surname>de Boer</surname><given-names>TP</given-names></name>, <name><surname>Smits</surname><given-names>AM</given-names></name>, <name><surname>van Laake</surname><given-names>LW</given-names></name>, <name><surname>van Vliet</surname><given-names>P</given-names></name>, <name><surname>Metz</surname><given-names>CHG</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro</article-title>. <source>Stem Cell Res</source>
<volume>1</volume>: <fpage>138</fpage>&#x02013;<lpage>149</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.scr.2008.02.003">10.1016/j.scr.2008.02.003</ext-link></comment>
</mixed-citation></ref><ref id="pone.0143953.ref005"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Smits</surname><given-names>AM</given-names></name>, <name><surname>van Laake</surname><given-names>LW</given-names></name>, <name><surname>den Ouden</surname><given-names>K</given-names></name>, <name><surname>Schreurs</surname><given-names>C</given-names></name>, <name><surname>Szuhai</surname><given-names>K</given-names></name>, <name><surname>van Echteld</surname><given-names>CJ</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium</article-title>. <source>Cardiovasc Res</source>
<volume>83</volume>: <fpage>527</fpage>&#x02013;<lpage>535</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cvr/cvp146">10.1093/cvr/cvp146</ext-link></comment>
<pub-id pub-id-type="pmid">19429921</pub-id></mixed-citation></ref><ref id="pone.0143953.ref006"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Van der Spoel</surname><given-names>TIG</given-names></name>, <name><surname>Jansen Of Lorkeers</surname><given-names>SJ</given-names></name>, <name><surname>Agostoni</surname><given-names>P</given-names></name>, <name><surname>van Belle</surname><given-names>E</given-names></name>, <name><surname>Gy&#x000f6;ngy&#x000f6;si</surname><given-names>M</given-names></name>, <name><surname>Sluijter</surname><given-names>JPG</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease</article-title>. <source>Cardiovasc Res</source>
<volume>91</volume>: <fpage>649</fpage>&#x02013;<lpage>658</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cvr/cvr113">10.1093/cvr/cvr113</ext-link></comment>
<pub-id pub-id-type="pmid">21498423</pub-id></mixed-citation></ref><ref id="pone.0143953.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Koudstaal</surname><given-names>S</given-names></name>, <name><surname>Jansen of Lorkeers</surname><given-names>SJ</given-names></name>, <name><surname>Gho</surname><given-names>JMIH</given-names></name>, <name><surname>van Hout</surname><given-names>GPJ</given-names></name>, <name><surname>Jansen</surname><given-names>MS</given-names></name>, <name><surname>Gr&#x000fc;ndeman</surname><given-names>PF</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Myocardial infarction and functional outcome assessment in pigs</article-title>. <source>J Vis Exp</source>: <fpage>1</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3791/51269">10.3791/51269</ext-link></comment>
</mixed-citation></ref><ref id="pone.0143953.ref008"><label>8</label><mixed-citation publication-type="book">
<collab>Zorginstituut Nederland</collab> (<year>2013</year>) <source>Farmacotherapeutisch Kompas</source>.</mixed-citation></ref><ref id="pone.0143953.ref009"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Van Hout</surname><given-names>GP</given-names></name>, <name><surname>de Jong</surname><given-names>R</given-names></name>, <name><surname>Vrijenhoek</surname><given-names>JE</given-names></name>, <name><surname>Timmers</surname><given-names>L</given-names></name>, <name><surname>Duckers</surname><given-names>HJ</given-names></name>, <name><surname>Hoefer</surname><given-names>IE</given-names></name> (<year>2013</year>) <article-title>Admittance based pressure volume loop measurements in a porcine model of chronic myocardial infarction</article-title>. <source>Exp Physiol</source>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1113/expphysiol.2013.074179">10.1113/expphysiol.2013.074179</ext-link></comment>
</mixed-citation></ref><ref id="pone.0143953.ref010"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Koudstaal</surname><given-names>S</given-names></name>, <name><surname>Jansen Of Lorkeers</surname><given-names>SJ</given-names></name>, <name><surname>van Slochteren</surname><given-names>FJ</given-names></name>, <name><surname>van der Spoel</surname><given-names>TIG</given-names></name>, <name><surname>van de Hoef</surname><given-names>TP</given-names></name>, <name><surname>Sluijter</surname><given-names>JPG</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Assessment of coronary microvascular resistance in the chronic infarcted pig heart</article-title>. <source>J Cell Mol Med</source>
<volume>17</volume>: <fpage>1128</fpage>&#x02013;<lpage>1135</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/jcmm.12089">10.1111/jcmm.12089</ext-link></comment>
<pub-id pub-id-type="pmid">23910946</pub-id></mixed-citation></ref><ref id="pone.0143953.ref011"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Koudstaal</surname><given-names>S</given-names></name>, <name><surname>Jansen of Lorkeers</surname><given-names>SJ</given-names></name>, <name><surname>Gaetani</surname><given-names>R</given-names></name>, <name><surname>Gho</surname><given-names>J</given-names></name>, <name><surname>van Slochteren</surname><given-names>FJ</given-names></name>
<name><surname>Slijter</surname><given-names>JPG</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Concise Review&#x0202f;: Heart Regeneration and the Role of Cardiac Stem Cells</article-title>. <source>Stem Cells Transl Med</source>
<volume>2</volume>: <fpage>434</fpage>&#x02013;<lpage>443</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5966/sctm.2013-0001">10.5966/sctm.2013-0001</ext-link></comment>
<pub-id pub-id-type="pmid">23658251</pub-id></mixed-citation></ref><ref id="pone.0143953.ref012"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Beltrami</surname><given-names>AP</given-names></name>, <name><surname>Barlucchi</surname><given-names>L</given-names></name>, <name><surname>Torella</surname><given-names>D</given-names></name>, <name><surname>Baker</surname><given-names>M</given-names></name>, <name><surname>Limana</surname><given-names>F</given-names></name>, <name><surname>Chimenti</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Adult cardiac stem cells are multipotent and support myocardial regeneration</article-title>. <source>Cell</source>
<volume>114</volume>: <fpage>763</fpage>&#x02013;<lpage>776</lpage>.
<pub-id pub-id-type="pmid">14505575</pub-id></mixed-citation></ref><ref id="pone.0143953.ref013"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Bearzi</surname><given-names>C</given-names></name>, <name><surname>Leri</surname><given-names>A</given-names></name>, <name><surname>Lo Monaco</surname><given-names>F</given-names></name>, <name><surname>Rota</surname><given-names>M</given-names></name>, <name><surname>Gonzalez</surname><given-names>A</given-names></name>, <name><surname>Hosoda</surname><given-names>Toru</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Identification of a coronary vascular progenitor cell in the human heart</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>106</volume>: <fpage>15885</fpage>&#x02013;<lpage>15890</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0907622106">10.1073/pnas.0907622106</ext-link></comment>
<pub-id pub-id-type="pmid">19717420</pub-id></mixed-citation></ref><ref id="pone.0143953.ref014"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Messina</surname><given-names>E</given-names></name>, <name><surname>De Angelis</surname><given-names>L</given-names></name>, <name><surname>Frati</surname><given-names>G</given-names></name>, <name><surname>Morrone</surname><given-names>S</given-names></name>, <name><surname>Chimenti</surname><given-names>S</given-names></name>, <name><surname>Fiordaliso</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Isolation and expansion of adult cardiac stem cells from human and murine heart</article-title>. <source>Circ Res</source>
<volume>95</volume>: <fpage>911</fpage>&#x02013;<lpage>921</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/01.RES.0000147315.71699.51">10.1161/01.RES.0000147315.71699.51</ext-link></comment>
<pub-id pub-id-type="pmid">15472116</pub-id></mixed-citation></ref><ref id="pone.0143953.ref015"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Gaetani</surname><given-names>R</given-names></name>, <name><surname>Feyen</surname><given-names>DAM</given-names></name>, <name><surname>Doevendans</surname><given-names>PA</given-names></name>, <name><surname>Gremmels</surname><given-names>H</given-names></name>, <name><surname>Fort</surname><given-names>E</given-names></name>, <name><surname>Fledderus</surname><given-names>JO</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Different type of cultured human adult Cardiac Progenitor Cells have a high degree od transcriptome similarity</article-title>. <source>J Mol Cell Cardiol</source>
<volume>18</volume>: <fpage>2147</fpage>&#x02013;<lpage>2151</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/jcmm.12458">10.1111/jcmm.12458</ext-link></comment>
</mixed-citation></ref><ref id="pone.0143953.ref016"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Jansen Of Lorkeers</surname><given-names>SJ</given-names></name>, <name><surname>Eding</surname><given-names>JEC</given-names></name>, <name><surname>Vesterinen</surname><given-names>HM</given-names></name>, <name><surname>van der Spoel</surname><given-names>TIG</given-names></name>, <name><surname>Sena</surname><given-names>ES</given-names></name>, <name><surname>Duckers</surname><given-names>HJ</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies</article-title>. <source>Circ Res</source>
<volume>116</volume>: <fpage>80</fpage>&#x02013;<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCRESAHA.116.304872">10.1161/CIRCRESAHA.116.304872</ext-link></comment>
<pub-id pub-id-type="pmid">25186794</pub-id></mixed-citation></ref><ref id="pone.0143953.ref017"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Johnston</surname><given-names>P V</given-names></name>, <name><surname>Sasano</surname><given-names>T</given-names></name>, <name><surname>Mills</surname><given-names>K</given-names></name>, <name><surname>Evers</surname><given-names>R</given-names></name>, <name><surname>Lee</surname><given-names>S-T</given-names></name>, <name><surname>Smith</surname><given-names>RR</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy</article-title>. <source>Circulation</source>
<volume>120</volume>: <fpage>1075</fpage>&#x02013;<lpage>1083</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.108.816058">10.1161/CIRCULATIONAHA.108.816058</ext-link></comment>
<pub-id pub-id-type="pmid">19738142</pub-id></mixed-citation></ref><ref id="pone.0143953.ref018"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Lee</surname><given-names>S-T</given-names></name>, <name><surname>White</surname><given-names>AJ</given-names></name>, <name><surname>Matsushita</surname><given-names>S</given-names></name>, <name><surname>Malliaras</surname><given-names>K</given-names></name>, <name><surname>Steenbergen</surname><given-names>C</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>
<volume>57</volume>: <fpage>455</fpage>&#x02013;<lpage>465</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jacc.2010.07.049">10.1016/j.jacc.2010.07.049</ext-link></comment>
<pub-id pub-id-type="pmid">21251587</pub-id></mixed-citation></ref><ref id="pone.0143953.ref019"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Malliaras</surname><given-names>K</given-names></name>, <name><surname>Li</surname><given-names>T-S</given-names></name>, <name><surname>Luthringer</surname><given-names>D</given-names></name>, <name><surname>Terrovitis</surname><given-names>J</given-names></name>, <name><surname>Cheng</surname><given-names>K</given-names></name>, <name><surname>Chakravarty</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells</article-title>. <source>Circulation</source>
<volume>125</volume>: <fpage>100</fpage>&#x02013;<lpage>112</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.111.042598">10.1161/CIRCULATIONAHA.111.042598</ext-link></comment>
<pub-id pub-id-type="pmid">22086878</pub-id></mixed-citation></ref><ref id="pone.0143953.ref020"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Kanazawa</surname><given-names>H</given-names></name>, <name><surname>Tseliou</surname><given-names>E</given-names></name>, <name><surname>Malliaras</surname><given-names>K</given-names></name>, <name><surname>Yee</surname><given-names>K</given-names></name>, <name><surname>Dawkins</surname><given-names>JF</given-names></name>, <name><surname>De Couto</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Cellular Post-Conditioning&#x0202f;: Allogeneic Cardiosphere-Derived Cells Reduce Infarct Size and Attenuate Microvascular Obstruction When Administered After Reperfusion in Pigs With Acute Myocardial Infarction</article-title>. <source>Circ Heart Fail</source>
<volume>8</volume>: <fpage>322</fpage>&#x02013;<lpage>332</lpage>.
<pub-id pub-id-type="pmid">25587096</pub-id></mixed-citation></ref><ref id="pone.0143953.ref021"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Yee</surname><given-names>K</given-names></name>, <name><surname>Malliaras</surname><given-names>K</given-names></name>, <name><surname>Kanazawa</surname><given-names>H</given-names></name>, <name><surname>Tseliou</surname><given-names>E</given-names></name>, <name><surname>Cheng</surname><given-names>K</given-names></name>, <name><surname>Luthringer</surname><given-names>DJ</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Allogeneic Cardiospheres Delivered via Percutaneous Transendocardial Injection Increase Viable Myocardium, Decrease Scar Size, and Attenuate Cardiac Dilatation in Porcine Ischemic Cardiomyopathy</article-title>. <source>PLoS One</source>
<volume>9</volume>: <fpage>e113805</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0113805">10.1371/journal.pone.0113805</ext-link></comment>
<pub-id pub-id-type="pmid">25460005</pub-id></mixed-citation></ref><ref id="pone.0143953.ref022"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Williams</surname><given-names>AR</given-names></name>, <name><surname>Hatzistergos</surname><given-names>KE</given-names></name>, <name><surname>Addicott</surname><given-names>B</given-names></name>, <name><surname>McCall</surname><given-names>F</given-names></name>, <name><surname>Carvalho</surname><given-names>D</given-names></name>, <name><surname>Suncion</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Enhanced Effect of Human Cardiac Stem Cells and Bone Marrow Mesenchymal Stem Cells to Reduce Infarct Size and Restore Cardiac Function after Myocardial Infarction</article-title>. <source>Circulation</source>
<volume>15</volume>: <fpage>213</fpage>&#x02013;<lpage>223</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.112.131110">10.1161/CIRCULATIONAHA.112.131110</ext-link></comment>
</mixed-citation></ref><ref id="pone.0143953.ref023"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Bolli</surname><given-names>R</given-names></name>, <name><surname>Tang</surname><given-names>X-L</given-names></name>, <name><surname>Sanganalmath</surname><given-names>SK</given-names></name>, <name><surname>Rimoldi</surname><given-names>O</given-names></name>, <name><surname>Mosna</surname><given-names>F</given-names></name>, <name><surname>Abdel-Latif</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy</article-title>. <source>Circulation</source>
<volume>128</volume>: <fpage>122</fpage>&#x02013;<lpage>131</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.112.001075">10.1161/CIRCULATIONAHA.112.001075</ext-link></comment>
<pub-id pub-id-type="pmid">23757309</pub-id></mixed-citation></ref><ref id="pone.0143953.ref024"><label>24</label><mixed-citation publication-type="journal">
<name><surname>De Rosa</surname><given-names>S</given-names></name>, <name><surname>Seeger</surname><given-names>FH</given-names></name>, <name><surname>Honold</surname><given-names>J</given-names></name>, <name><surname>Fischer-Rasokat</surname><given-names>U</given-names></name>, <name><surname>Lehmann</surname><given-names>R</given-names></name>, <name><surname>Fichtlscherer</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Procedural safety and predictors of acute outcome of intracoronary administration of progenitor cells in 775 consecutive procedures performed for acute myocardial infarction or chronic heart failure</article-title>. <source>Circ Cardiovasc Interv</source>
<volume>6</volume>: <fpage>44</fpage>&#x02013;<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCINTERVENTIONS.112.971705">10.1161/CIRCINTERVENTIONS.112.971705</ext-link></comment>
<pub-id pub-id-type="pmid">23362308</pub-id></mixed-citation></ref><ref id="pone.0143953.ref025"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Freyman</surname><given-names>T</given-names></name>, <name><surname>Polin</surname><given-names>G</given-names></name>, <name><surname>Osman</surname><given-names>H</given-names></name>, <name><surname>Crary</surname><given-names>J</given-names></name>, <name><surname>Lu</surname><given-names>M</given-names></name>, <name><surname>Chen</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction</article-title>. <source>Eur Heart J</source>
<volume>27</volume>: <fpage>1114</fpage>&#x02013;<lpage>1122</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/ehi818">10.1093/eurheartj/ehi818</ext-link></comment>
<pub-id pub-id-type="pmid">16510464</pub-id></mixed-citation></ref><ref id="pone.0143953.ref026"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Perin</surname><given-names>EC</given-names></name>, <name><surname>Silva</surname><given-names>GV</given-names></name>, <name><surname>Assad</surname><given-names>JAR</given-names></name>, <name><surname>Vela</surname><given-names>D</given-names></name>, <name><surname>Buja</surname><given-names>LM</given-names></name>, <name><surname>Sousa</surname><given-names>ALS</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction</article-title>. <source>J Mol Cell Cardiol</source>
<volume>44</volume>: <fpage>486</fpage>&#x02013;<lpage>495</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.yjmcc.2007.09.012">10.1016/j.yjmcc.2007.09.012</ext-link></comment>
<pub-id pub-id-type="pmid">18061611</pub-id></mixed-citation></ref><ref id="pone.0143953.ref027"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Van der Spoel</surname><given-names>TIG</given-names></name>, <name><surname>Vrijsen</surname><given-names>KR</given-names></name>, <name><surname>Koudstaal</surname><given-names>S</given-names></name>, <name><surname>Sluijter</surname><given-names>JPG</given-names></name>, <name><surname>Nijsen</surname><given-names>JFW</given-names></name>, <name><surname>de Jong</surname><given-names>HW</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Transendocardial cell injection is not superior to intracoronary infusion in a porcine model of ischaemic cardiomyopathy: a study on delivery efficiency</article-title>. <source>J Cell Mol Med</source>
<volume>16</volume>: <fpage>2768</fpage>&#x02013;<lpage>2776</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1582-4934.2012.01594.x">10.1111/j.1582-4934.2012.01594.x</ext-link></comment>
<pub-id pub-id-type="pmid">22697212</pub-id></mixed-citation></ref><ref id="pone.0143953.ref028"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Fukushima</surname><given-names>S</given-names></name>, <name><surname>Coppen</surname><given-names>SR</given-names></name>, <name><surname>Lee</surname><given-names>J</given-names></name>, <name><surname>Yamahara</surname><given-names>K</given-names></name>, <name><surname>Felkin</surname><given-names>LE</given-names></name>, <name><surname>Terracciano</surname><given-names>CMN</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Choice of cell-delivery route for skeletal myoblast transplantation for treating post-infarction chronic heart failure in rat</article-title>. <source>PLoS One</source>
<volume>3</volume>: <fpage>e3071</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0003071">10.1371/journal.pone.0003071</ext-link></comment>
<pub-id pub-id-type="pmid">18728781</pub-id></mixed-citation></ref><ref id="pone.0143953.ref029"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Ang</surname><given-names>K-L</given-names></name>, <name><surname>Chin</surname><given-names>D</given-names></name>, <name><surname>Leyva</surname><given-names>F</given-names></name>, <name><surname>Foley</surname><given-names>P</given-names></name>, <name><surname>Kubal</surname><given-names>C</given-names></name>,<name><surname>Chalil</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone</article-title>. <source>Nat Clin Pract Cardiovasc Med</source>
<volume>5</volume>: <fpage>663</fpage>&#x02013;<lpage>670</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncpcardio1321">10.1038/ncpcardio1321</ext-link></comment>
<pub-id pub-id-type="pmid">18711405</pub-id></mixed-citation></ref><ref id="pone.0143953.ref030"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Felix</surname><given-names>NJ</given-names></name>, <name><surname>Allen</surname><given-names>PM</given-names></name> (<year>2007</year>) <article-title>Specificity of T-cell alloreactivity</article-title>. <source>Nat Rev Immunol</source>
<volume>7</volume>: <fpage>942</fpage>&#x02013;<lpage>953</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nri2200">10.1038/nri2200</ext-link></comment>
<pub-id pub-id-type="pmid">18007679</pub-id></mixed-citation></ref><ref id="pone.0143953.ref031"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Matsuda</surname><given-names>S</given-names></name>, <name><surname>Koyasu</surname><given-names>S</given-names></name> (<year>2000</year>) <article-title>Mechanisms of action of cyclosporine</article-title>. <source>Immunopharmacology</source>
<volume>47</volume>: <fpage>119</fpage>&#x02013;<lpage>125</lpage>.
<pub-id pub-id-type="pmid">10878286</pub-id></mixed-citation></ref><ref id="pone.0143953.ref032"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Piot</surname><given-names>C</given-names></name>, <name><surname>Croisille</surname><given-names>P</given-names></name>, <name><surname>Staat</surname><given-names>P</given-names></name>, <name><surname>Thibault</surname><given-names>H</given-names></name>, <name><surname>Rioufol</surname><given-names>G</given-names></name>, <name><surname>Mewton</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Effect of cyclosporine on reperfusion injury in acute myocardial infarction</article-title>. <source>N Engl J Med</source>
<volume>359</volume>: <fpage>473</fpage>&#x02013;<lpage>481</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa071142">10.1056/NEJMoa071142</ext-link></comment>
<pub-id pub-id-type="pmid">18669426</pub-id></mixed-citation></ref><ref id="pone.0143953.ref033"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Jansen Of Lorkeers</surname><given-names>SJ</given-names></name>, <name><surname>Hart</surname><given-names>E</given-names></name>, <name><surname>Tang</surname><given-names>XL</given-names></name>, <name><surname>Chamuleau</surname><given-names>MED</given-names></name>, <name><surname>Doevendans</surname><given-names>PA</given-names></name>, <name><surname>Bolli</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Cyclosporin in Cell Therapy for Cardiac Regeneration</article-title>. <source>J Cardiovasc Transl Res</source>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12265-014-9570-8">10.1007/s12265-014-9570-8</ext-link></comment>
</mixed-citation></ref><ref id="pone.0143953.ref034"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Jeevanantham</surname><given-names>V</given-names></name>, <name><surname>Butler</surname><given-names>M</given-names></name>, <name><surname>Saad</surname><given-names>A</given-names></name>, <name><surname>Abdel-Latif</surname><given-names>A</given-names></name>, <name><surname>Zuba-Surma</surname><given-names>EK</given-names></name> and <name><surname>Dawn</surname><given-names>B</given-names></name>.(<year>2012</year>) <article-title>Adult Bone Marrow Cell Therapy Improves Survival and Induces Long-Term Improvement in Cardiac Parameters: A Systematic Review and Meta-Analysis</article-title>. <source>Circulation</source>
<volume>126</volume>: <fpage>551</fpage>&#x02013;<lpage>568</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.111.086074">10.1161/CIRCULATIONAHA.111.086074</ext-link></comment>
<pub-id pub-id-type="pmid">22730444</pub-id></mixed-citation></ref><ref id="pone.0143953.ref035"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Gnecchi</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Ni</surname><given-names>A</given-names></name>, <name><surname>Dzau</surname><given-names>VJ</given-names></name> (<year>2008</year>) <article-title>Paracrine mechanisms in adult stem cell signaling and therapy</article-title>. <source>Circ Res</source>
<volume>103</volume>: <fpage>1204</fpage>&#x02013;<lpage>1219</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCRESAHA.108.176826">10.1161/CIRCRESAHA.108.176826</ext-link></comment>
<pub-id pub-id-type="pmid">19028920</pub-id></mixed-citation></ref><ref id="pone.0143953.ref036"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Sanganalmath</surname><given-names>SK</given-names></name>, <name><surname>Bolli</surname><given-names>R</given-names></name> (<year>2013</year>) <article-title>Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions</article-title>. <source>Circ Res</source>
<volume>113</volume>: <fpage>810</fpage>&#x02013;<lpage>834</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCRESAHA.113.300219">10.1161/CIRCRESAHA.113.300219</ext-link></comment>
<pub-id pub-id-type="pmid">23989721</pub-id></mixed-citation></ref><ref id="pone.0143953.ref037"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Sena</surname><given-names>E</given-names></name>, <name><surname>van der Worp</surname><given-names>HB</given-names></name>, <name><surname>Howells</surname><given-names>D</given-names></name>, <name><surname>Macleod</surname><given-names>M</given-names></name> (<year>2007</year>) <article-title>How can we improve the pre-clinical development of drugs for stroke?</article-title>
<source>Trends Neurosci</source>
<volume>30</volume>: <fpage>433</fpage>&#x02013;<lpage>439</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.tins.2007.06.009">10.1016/j.tins.2007.06.009</ext-link></comment>
<pub-id pub-id-type="pmid">17765332</pub-id></mixed-citation></ref><ref id="pone.0143953.ref038"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Chong</surname><given-names>JJH</given-names></name>, <name><surname>Yang</surname><given-names>X</given-names></name>, <name><surname>Don</surname><given-names>CW</given-names></name>, <name><surname>Minami</surname><given-names>E</given-names></name>, <name><surname>Liu</surname><given-names>Y-W</given-names></name>, <name><surname>Weyers</surname><given-names>JJ</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts</article-title>. <source>Nature</source>
<volume>510</volume>: <fpage>273</fpage>&#x02013;<lpage>277</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature13233">10.1038/nature13233</ext-link></comment>
<pub-id pub-id-type="pmid">24776797</pub-id></mixed-citation></ref><ref id="pone.0143953.ref039"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Ye</surname><given-names>L</given-names></name>, <name><surname>Chang</surname><given-names>Y-H</given-names></name>, <name><surname>Xiong</surname><given-names>Q</given-names></name>, <name><surname>Zhang</surname><given-names>P</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Somasundaram</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells</article-title>. <source>Cell Stem Cell</source>
<volume>15</volume>: <fpage>750</fpage>&#x02013;<lpage>761</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.stem.2014.11.009">10.1016/j.stem.2014.11.009</ext-link></comment>
<pub-id pub-id-type="pmid">25479750</pub-id></mixed-citation></ref><ref id="pone.0143953.ref040"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Sch&#x000e4;chinger</surname><given-names>V</given-names></name>, <name><surname>Erbs</surname><given-names>S</given-names></name>, <name><surname>Els&#x000e4;sser</surname><given-names>A</given-names></name>, <name><surname>Haberbosch</surname><given-names>W</given-names></name>, <name><surname>Hambrecht</surname><given-names>R</given-names></name>, <name><surname>H&#x000f6;lschermann</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial</article-title>. <source>Eur Heart J</source>
<volume>27</volume>: <fpage>2775</fpage>&#x02013;<lpage>2783</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/ehl388">10.1093/eurheartj/ehl388</ext-link></comment>
<pub-id pub-id-type="pmid">17098754</pub-id></mixed-citation></ref><ref id="pone.0143953.ref041"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Delewi</surname><given-names>R</given-names></name>, <name><surname>Hirsch</surname><given-names>A</given-names></name>, <name><surname>Tijssen</surname><given-names>JG</given-names></name>, <name><surname>Sch&#x000e4;chinger</surname><given-names>V</given-names></name>, <name><surname>Wojakowski</surname><given-names>W</given-names></name>, <name><surname>Roncalli</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis</article-title>. <source>Eur Heart J</source>
<volume>35</volume>: <fpage>989</fpage>&#x02013;<lpage>998</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/eht372">10.1093/eurheartj/eht372</ext-link></comment>
<pub-id pub-id-type="pmid">24026778</pub-id></mixed-citation></ref><ref id="pone.0143953.ref042"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Oh</surname><given-names>H</given-names></name>, <name><surname>Bradfute</surname><given-names>SB</given-names></name>, <name><surname>Gallardo</surname><given-names>TD</given-names></name>, <name><surname>Nakamura</surname><given-names>T</given-names></name>, <name><surname>Gaussin</surname><given-names>V</given-names></name>, <name><surname>Mishina</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>100</volume>: <fpage>12313</fpage>&#x02013;<lpage>12318</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.2132126100">10.1073/pnas.2132126100</ext-link></comment>
<pub-id pub-id-type="pmid">14530411</pub-id></mixed-citation></ref></ref-list></back></article>